Economy/Home · Economy

[Breaking] Aprogen and Yuhan Corporation Finalize Joint R&D Contract for TIGIT Antibody Drug — Settlement of 1 Billion Won

Aprogen announced in a regulatory filing on the 30th that it has signed an amended contract to finalize the joint research and development agreement concluded with Yuhan Corporation in 2016 for the discovery of a TIGIT-targeted antibody drug candidate. The settlement amount is 1 billion won, and the

Oseong Kwon
Staff Reporter
3 min read
[Breaking] Aprogen and Yuhan Corporation Finalize Joint R&D Contract for TIGIT Antibody Drug — Settlement of 1 Billion Won
CBC News

Aprogen announced in a regulatory filing on the 30th that it has signed an amended contract to finalize the joint research and development agreement concluded with Yuhan Corporation in 2016 for the discovery of a TIGIT-targeted antibody drug candidate. The settlement amount is 1 billion won, and the date of the amended contract is October 30, 2026.

All Rights to Research Outcomes to Belong to Yuhan Corporation

The amended contract contains provisions under mutual agreement between the two companies to complete the performance of the existing agreement and to vest all related research outcomes in Yuhan Corporation. Under the contract, all rights related to the research outcomes, including the technology transfer of the candidate substance, belong to Yuhan Corporation, and the related rights and obligations are finally settled.

No Additional Performance Obligations or Contingent Liabilities

The company explained that the settlement amount corresponds to 10% or more of its revenue in the most recent fiscal year, making it subject to mandatory disclosure. Aprogen stated that with the signing of the amended contract, the R&D project under the original agreement has been fully completed and settled, and accordingly, there are no additional performance obligations or contingent liabilities.

Meanwhile, the company noted that the original joint R&D agreement was signed in 2016 when Aprogen was an unlisted company, and there was no separate disclosure record at that time.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.